MedTrace Logo

The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention

NCT05318456 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-03-22

No results posted yet for this study

Summary

The objective of this study is to investigate the efficacy and safety of MoodElite T-4003-1 on improving mood in a healthy adult population with mild to moderate depressive symptoms not eligible for therapeutic intervention.

Conditions

  • Mood

Interventions

DIETARY_SUPPLEMENT

MoodElite T-4003-1

Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.

DIETARY_SUPPLEMENT

Comparator

Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.

OTHER

Placebo

Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.

Sponsors & Collaborators

  • KGK Science Inc.

    collaborator INDUSTRY

  • Chenland Nutritionals Inc.

    lead INDUSTRY

Principal Investigators

  • David Crowley, MD · KGK Science Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-24
Primary Completion
2023-01-19
Completion
2023-03-20

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05318456 on ClinicalTrials.gov